Please enable JavaScript to continue using this application.

Compare $GOSS vs $XLO | Chartloom

Compare

$GOSS vs $XLO

Gossamer Bio Inc · Xilio Therapeutics Inc

GOSS

Gossamer Bio Inc

XLO

Xilio Therapeutics Inc

Compare $GOSS vs $XLO

Comparing Gossamer Bio Inc and Xilio Therapeutics Inc

GOSSGossamer Bio Inc

XLOXilio Therapeutics Inc

GOSSGossamer Bio Inc

Market cap

$4.55B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

32.4%

YTD performance

-96.0%

52W performance

-95.2%

FCF yield

-3.6%

XLOXilio Therapeutics Inc

Market cap

$54M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.42x

Rev growth (TTM)

327.3%

YTD performance

-3.8%

52W performance

-23.1%

FCF yield

-113.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GOSS

XLO

Detailed metrics comparison

GOSS

Gossamer Bio Inc

XLO

Xilio Therapeutics Inc

Market Cap

GOSS$4.55B

XLO$54M

Enterprise Value

GOSS$4.55B

XLO$-82M

Price

GOSS$9.31

XLO$9.05

P/E Ratio

GOSSN/A

XLON/A

P/S Ratio

GOSS85.41x

XLO0.84x

EV/Sales

GOSS85.32x

XLO-1.28x

EV/EBITDA

GOSS0.00x

XLO0.00x

P/B Ratio

GOSS2.26x

XLO0.82x

P/FCF Ratio

GOSSN/A

XLON/A

EV/FCF

GOSS-27.95x

XLO1.34x

PEG Ratio

GOSSN/A

XLON/A

Forward P/E (NTM)

GOSSN/A

XLON/A

Forward P/S (NTM)

GOSSN/A

XLO3.42x

Revenue (TTM)

GOSS$53M

XLO$64M

Revenue Growth (YoY)

GOSS32.4%

XLO327.3%

Forward Rev Growth

GOSS50.5%

XLO-34.2%

Gross Margin (TTM)

GOSS0.0%

XLO0.0%

Operating Margin (TTM)

GOSS0.0%

XLO0.0%

EBITDA Margin (TTM)

GOSS-297.6%

XLO-46.9%

Net Margin (TTM)

GOSS-235.0%

XLO-34.1%

FCF Margin (TTM)

GOSS-305.2%

XLO-95.6%

Net Income (TTM)

GOSS$-125M

XLO$-22M

FCF (TTM)

GOSS$-163M

XLO$-61M

EPS (TTM)

GOSS-$0.38

XLO-$1.12

ROE (TTM)

GOSS-11877.0%

XLO-923.0%

ROA (TTM)

GOSS-8535.0%

XLO-1441.0%

ROIC (TTM)

GOSS-2300.0%

XLO-923.0%

Cash

GOSS$41M

XLO$136M

Debt

GOSS$36M

XLO$0

Net Cash/Debt

GOSS$5M

XLO$136M

Current Ratio (TTM)

GOSS0.53x

XLO4.25x

Quick Ratio (TTM)

GOSS0.46x

XLO4.15x

Debt/Equity (TTM)

GOSS6.83x

XLO0.00x

Debt/Assets (TTM)

GOSS0.0%

XLO0.0%

Interest Coverage (TTM)

GOSSN/A

XLON/A

Net Debt/EBITDA (TTM)

GOSS0.00x

XLO0.00x

Beta

GOSS2.28

XLO-0.12

52W Performance

GOSS-95.2%

XLO-23.1%

YTD Performance

GOSS-96.0%

XLO-3.8%

% from 52W High

GOSS-97.0%

XLO-28.1%

% from 52W Low

GOSS2.3%

XLO40.0%

Asset Turnover (TTM)

GOSS0.36x

XLO0.42x

FCF Yield (TTM)

GOSS-3.6%

XLO-113.2%

Earnings Yield (TTM)

GOSS-2.8%

XLO-40.3%

Dividend Yield (TTM)

GOSSN/A

XLON/A

Rule of 40

GOSS-272.8

XLO231.7

EV/GP/RG

GOSSN/A

XLON/A

Ticker research

View GOSS research View XLO research

Metric	GOSS Gossamer Bio Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$4.55B	$54M
Enterprise Value	$4.55B	$-82M
Price	$9.31	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	85.41x	0.84x
EV/Sales	85.32x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.26x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-27.95x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.42x
Revenue & Growth
Revenue (TTM)	$53M	$64M
Revenue Growth (YoY)	32.4%	327.3%
Forward Rev Growth	50.5%	-34.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-297.6%	-46.9%
Net Margin (TTM)	-235.0%	-34.1%
FCF Margin (TTM)	-305.2%	-95.6%
Net Income (TTM)	$-125M	$-22M
FCF (TTM)	$-163M	$-61M
EPS (TTM)	-$0.38	-$1.12
ROE (TTM)	-11877.0%	-923.0%
ROA (TTM)	-8535.0%	-1441.0%
ROIC (TTM)	-2300.0%	-923.0%
Financial Health
Cash	$41M	$136M
Debt	$36M	$0
Net Cash/Debt	$5M	$136M
Current Ratio (TTM)	0.53x	4.25x
Quick Ratio (TTM)	0.46x	4.15x
Debt/Equity (TTM)	6.83x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.28	-0.12
52W Performance	-95.2%	-23.1%
YTD Performance	-96.0%	-3.8%
% from 52W High	-97.0%	-28.1%
% from 52W Low	2.3%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.36x	0.42x
FCF Yield (TTM)	-3.6%	-113.2%
Earnings Yield (TTM)	-2.8%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-272.8	231.7
EV/GP/RG	N/A	N/A
Ticker research	View GOSS research	View XLO research

Valuation

P/S Ratio

XLO

0.84x

GOSS

85.41x

EV/FCF

GOSS

-27.95x

XLO

1.34x

Growth & revenue

Revenue Growth TTM

XLO

327.3%

GOSS

32.4%

Forward Revenue Growth

GOSS

50.5%

XLO

-34.2%

Profitability & performance

Gross Margin

GOSS

0.0%

XLO

0.0%

ROE

XLO

-923.0%

GOSS

-11877.0%

FCF Yield %

GOSS

-3.6%

XLO

-113.2%

52-Week Performance

XLO

-23.1%

GOSS

-95.2%

Detailed metrics comparison

GOSS

Gossamer Bio Inc

XLO

Xilio Therapeutics Inc

Market Cap

GOSS$4.55B

XLO$54M

Enterprise Value

GOSS$4.55B

XLO$-82M

Price

GOSS$9.31

XLO$9.05

P/E Ratio

GOSSN/A

XLON/A

P/S Ratio

GOSS85.41x

XLO0.84x

EV/Sales

GOSS85.32x

XLO-1.28x

EV/EBITDA

GOSS0.00x

XLO0.00x

P/B Ratio

GOSS2.26x

XLO0.82x

P/FCF Ratio

GOSSN/A

XLON/A

EV/FCF

GOSS-27.95x

XLO1.34x

PEG Ratio

GOSSN/A

XLON/A

Forward P/E (NTM)

GOSSN/A

XLON/A

Forward P/S (NTM)

GOSSN/A

XLO3.42x

Revenue (TTM)

GOSS$53M

XLO$64M

Revenue Growth (YoY)

GOSS32.4%

XLO327.3%

Forward Rev Growth

GOSS50.5%

XLO-34.2%

Gross Margin (TTM)

GOSS0.0%

XLO0.0%

Operating Margin (TTM)

GOSS0.0%

XLO0.0%

EBITDA Margin (TTM)

GOSS-297.6%

XLO-46.9%

Net Margin (TTM)

GOSS-235.0%

XLO-34.1%

FCF Margin (TTM)

GOSS-305.2%

XLO-95.6%

Net Income (TTM)

GOSS$-125M

XLO$-22M

FCF (TTM)

GOSS$-163M

XLO$-61M

EPS (TTM)

GOSS-$0.38

XLO-$1.12

ROE (TTM)

GOSS-11877.0%

XLO-923.0%

ROA (TTM)

GOSS-8535.0%

XLO-1441.0%

ROIC (TTM)

GOSS-2300.0%

XLO-923.0%

Cash

GOSS$41M

XLO$136M

Debt

GOSS$36M

XLO$0

Net Cash/Debt

GOSS$5M

XLO$136M

Current Ratio (TTM)

GOSS0.53x

XLO4.25x

Quick Ratio (TTM)

GOSS0.46x

XLO4.15x

Debt/Equity (TTM)

GOSS6.83x

XLO0.00x

Debt/Assets (TTM)

GOSS0.0%

XLO0.0%

Interest Coverage (TTM)

GOSSN/A

XLON/A

Net Debt/EBITDA (TTM)

GOSS0.00x

XLO0.00x

Beta

GOSS2.28

XLO-0.12

52W Performance

GOSS-95.2%

XLO-23.1%

YTD Performance

GOSS-96.0%

XLO-3.8%

% from 52W High

GOSS-97.0%

XLO-28.1%

% from 52W Low

GOSS2.3%

XLO40.0%

Asset Turnover (TTM)

GOSS0.36x

XLO0.42x

FCF Yield (TTM)

GOSS-3.6%

XLO-113.2%

Earnings Yield (TTM)

GOSS-2.8%

XLO-40.3%

Dividend Yield (TTM)

GOSSN/A

XLON/A

Rule of 40

GOSS-272.8

XLO231.7

EV/GP/RG

GOSSN/A

XLON/A

Ticker research

View GOSS research View XLO research

Metric	GOSS Gossamer Bio Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$4.55B	$54M
Enterprise Value	$4.55B	$-82M
Price	$9.31	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	85.41x	0.84x
EV/Sales	85.32x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.26x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-27.95x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.42x
Revenue & Growth
Revenue (TTM)	$53M	$64M
Revenue Growth (YoY)	32.4%	327.3%
Forward Rev Growth	50.5%	-34.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-297.6%	-46.9%
Net Margin (TTM)	-235.0%	-34.1%
FCF Margin (TTM)	-305.2%	-95.6%
Net Income (TTM)	$-125M	$-22M
FCF (TTM)	$-163M	$-61M
EPS (TTM)	-$0.38	-$1.12
ROE (TTM)	-11877.0%	-923.0%
ROA (TTM)	-8535.0%	-1441.0%
ROIC (TTM)	-2300.0%	-923.0%
Financial Health
Cash	$41M	$136M
Debt	$36M	$0
Net Cash/Debt	$5M	$136M
Current Ratio (TTM)	0.53x	4.25x
Quick Ratio (TTM)	0.46x	4.15x
Debt/Equity (TTM)	6.83x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.28	-0.12
52W Performance	-95.2%	-23.1%
YTD Performance	-96.0%	-3.8%
% from 52W High	-97.0%	-28.1%
% from 52W Low	2.3%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.36x	0.42x
FCF Yield (TTM)	-3.6%	-113.2%
Earnings Yield (TTM)	-2.8%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-272.8	231.7
EV/GP/RG	N/A	N/A
Ticker research	View GOSS research	View XLO research